Headquartered in Germantown, MD Fiscal year ends December NASDAQ: PGEN precigen.com
Precigen, Inc. (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. The company's flagship product, PAPZIMEOS (zopapogene imadenovec-drba), is the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), an HPV-driven disease. PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy that generates an immune response against HPV 6 and HPV 11 proteins. Precigen's proprietary AdenoVerse platform underpins its pipeline, which includes PRGN-2009, an investigational immunotherapy in Phase 2 trials for HPV-associated cancers including oropharyngeal cancer and cervical cancer. The company's therapeutic focus spans immuno-oncology, autoimmune disorders, and infectious diseases. Precigen is pursuing global expansion of PAPZIMEOS, with a Marketing Authorization Application under review by the European Medicines Agency. Updated
Are you interested in investing in penny stocks? Though doing so does come with risk, making the right investment decisions in the penny stock category can produce eye-opening returns. While the profits…
A beneficial owner made a huge buy of shares in a trucking company this past week. That was not the only big insider buying though.
Precigen, Inc. (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need.
The Wall Street consensus 12-month price target for PGEN is $13.65.
